Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2002;39:389-393
doi: 10.1161/hy02t2.102809
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katki, K. A.
Right arrow Articles by DiPette, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katki, K. A.
Right arrow Articles by DiPette, D. J.
Related Collections
Right arrow Other hypertension
Right arrow Gene expression
Right arrow Hypertension - basic studies
Right arrow Physiological and pathological control of gene expression
Right arrow Other Vascular biology

(Hypertension. 2002;39:389.)
© 2002 American Heart Association, Inc.


Scientific Contributions

Substance P in Subtotal Nephrectomy-Salt Hypertension

Khurshed A. Katki; Scott C. Supowit; Donald J. DiPette

From the Michigan State University, College of Human Medicine, Department of Medicine, East Lansing, Mich.

Correspondence to Scott C. Supowit, PhD, Michigan State University, B-338 Clinical Center, East Lansing, MI 48824. E-mail scott.supowit{at}ht.msu.edu

We have previously demonstrated that calcitonin gene-related peptide (CGRP) plays a counterregulatory role in subtotal nephrectomy-salt (SN-salt) hypertension through an increase in vascular responsiveness to the dilator activity of this neuropeptide. Substance P (SP) is often co-localized with CGRP in perivascular sensory nerves. To determine the role and mechanism of action of SP in SN-salt hypertension, we induced hypertension in 4- to 6-week-old male Sprague-Dawley rats (n=8) by subtotal nephrectomy and 1% saline drinking water. Sham-operated rats were given either tap water (n=9) or 1% saline to drink (n=9). Eleven to 13 days after each protocol, all rats had intravenous (for drug administration) and arterial (for continuous monitoring of mean arterial pressure [MAP]) catheters surgically implanted and were studied in the conscious and unrestrained state. Baseline MAP was significantly elevated in the SN-salt rats (157±6 mm Hg) compared with tap water–fed controls (128±3 mm Hg) and 1% saline–fed controls (132±5 mm Hg). Vehicle administration did not alter the MAP in any group. In contrast, administration of spantide-II (0.2 µmol/L in saline), an SP receptor antagonist, significantly elevated the MAP in SN-salt rats (13.9±0.8 mm Hg) compared with the tap water (1.7±1.7 mm Hg) and 1% saline controls (2.0±1.9 mm Hg). SP mRNA and peptide levels in dorsal root ganglia were not significantly different between the 3 groups. Administration of exogenous SP (12 and 24 nmol · L-1 · kg-1 intravenously) resulted in a significantly greater decrease in MAP in the SN-salt rats compared with both control groups. Taken together, these data suggest that in SN-salt hypertension, SP plays a counterregulatory role in the absence of an increase in its neuronal expression, thereby suggesting that one possible mechanism of this compensatory vasodilator response is enhanced vascular reactivity to SP.


Key Words: rats • neuropeptides • renal disease • blood pressure • RNA • radioimmunoassay




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. C. Supowit, R. T. Ethridge, H. Zhao, K. A. Katki, and D. J. DiPette
Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats
Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1169 - H1175.
[Abstract] [Full Text] [PDF]